Complex Karyotype is a Stronger Predictor than Del(17p) for Inferior Outcome in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens

BACKGROUND: Ibrutinib is active in patients with relapsed/refractory (R/R) CLL. In patients treated with ibrutinib for R/R CLL, del(17p) identified by interphase fluorescence in situ hybridization (FISH) is associated with inferior progression-free survival, despite equivalent initial response rates...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer
Main Authors: Thompson, Philip A., O’Brien, Susan M., Wierda, William G., Ferrajoli, Alessandra, Stingo, Francesco, Smith, Susan C., Burger, Jan A., Estrov, Zeev, Jain, Nitin, Kantarjian, Hagop M., Keating, Michael J.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4866653/
https://ncbi.nlm.nih.gov/pubmed/26193999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29566
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki